Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance
Ian C
IC
The Centre for Inflammatory Bowel Diseases, Fremantle Hospital, University of Western Australia, Fremantle, Western Australia, Australia. ian.lawrance@uwa.edu.au
Radford-Smith
Graham L
GL
Bampton
Peter A
PA
Andrews
Jane M
JM
Tan
Pok-Kern
PK
Croft
Anthony
A
Gearry
Richard B
RB
Florin
Timothy H J
TH
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D001315:Australia / Q000453:epidemiology; D001424:Bacterial Infections / Q000453:epidemiology / Q000382:microbiology; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006562:Herpes Zoster / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009520:New Zealand / Q000453:epidemiology; D009894:Opportunistic Infections / Q000453:epidemiology*; D014376:Tuberculosis / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab